<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>In vitro</italic> CQ revealed low half-maximal effective concentration (EC50) and high half-cytotoxic concentration (CC50) for COVID-19.
 <sup>
  <xref rid="bibr5-1759720X20947296" ref-type="bibr">5</xref>
 </sup> A preliminary study conducted in China showed benefits in pneumonia image, shortening of disease course, and promoting a virus-negative conversion compared with control group.
 <sup>
  <xref rid="bibr6-1759720X20947296" ref-type="bibr">6</xref>
 </sup> Then, four completed clinical studies demonstrated favorable outcomes in clinical and radiologic amelioration, while another two randomized controlled trials (RCTs) illustrated no statistically significant change compared with control arms.
 <sup>
  <xref rid="bibr7-1759720X20947296" ref-type="bibr">7</xref>
  <xref rid="bibr8-1759720X20947296" ref-type="bibr"/>
  <xref rid="bibr9-1759720X20947296" ref-type="bibr"/>
  <xref rid="bibr10-1759720X20947296" ref-type="bibr"/>
  <xref rid="bibr11-1759720X20947296" ref-type="bibr"/>â€“
  <xref rid="bibr12-1759720X20947296" ref-type="bibr">12</xref>
 </sup> Based on the inhibitory effect of azithromycin against Ebola and Zika viruses 
 <italic>in vitro</italic>, and the possibility of preventing from progressing to severe respiratory tract infections, two French trials which combined the use of azithromycin and HCQ revealed better efficacy.
 <sup>
  <xref rid="bibr7-1759720X20947296" ref-type="bibr">7</xref>,
  <xref rid="bibr9-1759720X20947296" ref-type="bibr">9</xref>
 </sup>
</p>
